BioSpace News Archive

CardioFocus, Inc ., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that Chief Executive Officer & President Burke T. Barrett will present at the 23rd Annual ICR Conference , being held virtually January 11-14, 2021 .

Today Nextrove, LLC., a rapidly growing integrator of pharmacovigilance and clinical solutions, announced that John (Doug) Sydow joined the company as Senior Advisor

Medly Pharmacy continues its nationwide expansion providing innovative prescription delivery services to the Raleigh, North Carolina market

Taiho Oncology, Inc. and Servier today announced that data for LONSURF ® (trifluridine and tipiracil) in previously treated patients with metastatic gastric cancer (mGC) and metastatic gastroesophageal junction adenocarcinoma (mGEJC) will be presented during the 2021 American Society of Clinical Oncology Gastrointestinal Cancers

As part of its ongoing commitment to advance transparency and efficiency in precision medicine, Concert Genetics announced the launch of a preferred network of genetic testing laboratories.

New results from the AI-EMERGE® study show Freenome’s multiomics blood test can detect colorectal advanced adenomas at 41% sensitivity and 90% specificity, which is comparable to or better than currently available non-invasive tests for colorectal cancer screening. This data, to be presented at ASCO-GI, build on previously reported data from a separate cohort that showed Freenome’s multiomics blood test can detect early-stage colorectal cancer

Humacyte, Inc., a leading innovator in regenerative medicine and biotechnology, announced that President and CEO Laura Niklason, M.D., Ph.D. will present virtually at the ICR Conference on January 14 at 12:15 p.m. EST. Dr. Niklason will present an overview of Humacyte’s groundbreaking regenerative medicine therapies, including the Company’s late-stage clinical programs in vascular trauma repair and AV access for hemodialysi

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders for Q4 2020.

Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, announced today that Mark Gelder , M.D., has been promoted to chief medical officer of Elevar Therapeutics.

Liminal BioSciences Inc. (Nasdaq: LMNL) , a clinical-stage biopharmaceutical company, announced that the Company’s wholly-owned subsidiary, Prometic Plasma Resources ( USA ) Inc., has received U.S. Food and Drug Administration approval for its plasma collection